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2214-031X/Copyright ª 2013, The Aut
license (http://creativecommons.org/Summary Our previous studies have demonstrated that the quaternised chitosan-loaded
polymethylmethacrylate (PMMA) is a promising new antibacterial bone cement. The aim of this
study was to evaluate biomechanical properties of quaternised chitosan-loaded PMMA in vitro
and interface histology between cement and bone in vivo. In this study, hydroxypropyltri-
methyl ammonium chloride chitosan (HACC) with 26% degree of substitution (referred to as
26% HACC) was loaded into PMMA bone cement at a 20% mass ratio, and the specimens of
26% HACC-loaded PMMA bone cement (PMMAeH) were prepared for compressive and bending
mechanical test according to ISO 5883-2002 standard prior to and after the 4-week immersion
in PBS. The chitosan-loaded PMMA bone cement (PMMAeC) at the same mass ratio, pure PMMA,
and gentamicin-loaded PMMA (PMMAeG) were also prepared and tested as controls. Then each
of four kinds of bone cements was implanted into the rabbit femoral condyle and the osseoin-
tegration of the cementebone interface was evaluated after its implantation over 6 weeks.
The results show that biomechanical properties of both PMMAeC and PMMAeH were reduced
significantly compared with the PMMA or PMMAeC, and the elastic modulus of PMMAeH was
close to that of human cancellous bone. Histological observation in animal studies indicates
that there was better osseointegration at the cementebone interface in the PMMAeH group
than that in the PMMA, PMMAeG, or PMMAeC groups. More new bone formation was found
around PMMAeH bone cement as compared with that in the other three groups. Our findings
indicated that the biomechanical properties of PMMAeH were reduced but close to that of
neighbouring bone. The PMMAeH had good biocompatibility and osseointegration potential,86 21 63137020.
ail.com (T. Tang).
06.002
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58 H. Tan et al.implying its suitability for vertebral augmentation of osteoporotic vertebral compression frac-
tures and fixation of prosthesis in cemented joint replacement.
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Percutaneous vertebroplasty and kyphoplasty have become
effective methods to treat osteoporotic vertebral fractures
[1,2]. The basic technique for surgical procedures is to
inject bone cement into the compressed vertebral body, and
the most widely used bone cement is poly-
methylmethacrylate (PMMA) [1e3]. However, the inherent
biological inertia of PMMA leads to poor osseointegration
between bone tissue and cement interface, apart from
other shortcomings such as nonabsorbability, monomer
toxicity, high polymerization temperature, bone cement
leakage, and adjacent vertebral fracture [1,2,4e7]. The
high compressive strength and modulus of PMMA cause a
biomechanical mismatch between treated and untreated
vertebral levels that may increase the risk of adjacent
vertebral body fractures [6,7]. In order to eliminate or
overcome these shortcomings of PMMA cement, hydroxyap-
atite, calcium phosphate, bioglass, titanium fibre, and chi-
tosan have been investigated to be incorporated into PMMA
to improve its physical and biological properties [8e13].
In addition, PMMA bone cement has been routinely used
for prosthesis fixation in total joint replacement, and
gentamicin-loaded PMMA bone cement has become the
standard practice for prevention or treatment of joint
infection [14e16]. An in vivo study showed that the con-
centration of gentamicin released from PMMA beads is up to
400e600 mg/mL on Day 1 following implantation into the
body [17]. An in vitro study demonstrated that the con-
centrations of gentamicin released from PMMA beads (0.2 g
with 4.5 mg gentamicin) were 600 mg/mL on Day 1, and
120 mg/mL on Day 10 [18]. These high concentrations of
gentamicin, which are enough to prevent or treat local in-
fections caused by susceptible bacterial strains, also far
exceed the critical level of 100 mg/mL for osteogenesis of
the osteogenic cells [19]. It has also been shown that
gentamicin at high local concentrations affects the prolif-
eration and differentiation of the osteogenic cells and
human bone marrow mesenchymal stem cells [19e26],
which may finally affect the osseointegration of the bone
cement interface. Therefore, it is necessary to find a new
antibacterial agent with good osteogenic activity instead of
the concept of impregnating antibiotics into PMMA bone
cement.
In previous studies, we have successfully developed a
PMMA bone cement loaded with a new water-soluble chi-
tosan derivative (hydroxypropyltrimethyl ammonium chlo-
ride chitosan, HACC) with a 26% degree of substitution (DS)
of the quaternary ammonium (referred to as 26% HACC)
[27,28]. Further in vitro study demonstrated that this bone
cement could inhibit bacterial biofilm formation on its
surface, and had a better osteogenic bioactivity compared
with gentamicin-loaded PMMA [27,28]. The purposes of the
current study were to investigate the impact of HACC onthe mechanical properties of the composite bone cement
according to the international standard for acrylic bone
cement, and to assess the osseointegration of the com-
posite bone cement in a rabbit model.
Materials and methods
Materials
The CMW Endurance Bone Cement containing PMMA/MMA
with or without gentamicin (DePuy International Ltd.,
Leeds, West Yorkshire, UK) was used in this study. HACC
with 26% DS was synthesized and characterized according to
a literature report [28]. The mould and test specimens used
for biomechanical testing were prepared according to the
ISO 5883-2002 standard [29]. The mould for the compres-
sion test was composed of polytetrafluoroethene (PTFE)
mould, endplate, knockout rod, and C-shape fixture. The
PTFE mould had an external diameter of 25 mm, height of
12  0.1 mm, and a diameter of internal hole of
6  0.1 mm. The final compression mechanical test spec-
imen was a cylinder with 12  0.1 mm in height and
6  0.1 mm in diameter. The mould for the bending test was
composed of PTFE mould, endplate, and C-shape fixture,
and the final test specimen measured
75 mm  10 mm  3.3 mm. The preparation of the mould
and mechanical testing specimens are shown in Fig. 1.
Determination of the mass ratio of HACC
incorporated into PMMA
HACC with 26% DS was incorporated into PMMA bone
cement powder with mass ratios of 15%, 20%, 30%, and 40%,
and mixed evenly using a high-speed mixer (Jintan Tech-
nology Ltd., Jintan, China). Then the powder was mixed
with the liquid monomer at a ratio of 1.5 mL/2 g [9]. Bone
cements were poured into a mould for the compression
test, and fixed with the metal endplate and C-shape fixture
for 4 h. After the bone cements were hardened, the PTFE
endplate and C-shape fixture were removed, and the cy-
lindrical test specimens were taken out for the biome-
chanical compression test [29].
The test was performed at 23  1 C [29], and both ends
of the cylindrical specimen were polished with corundum.
The specimen was placed on the mechanical test platform
(Instron 8874; Instron, Norwood, MA, USA), and loaded with
the fixed crosshead at a speed of 25 mm/min until rupture
of the materials (Fig. 2A). Loadedeformation curves and
stressestrain curves were plotted and the compressive
strength and modulus were automatically calculated and
recorded by the computer system. Each of five samples
with 12  0.1 mm in height and 6  0.1 in diameter was
tested.
Figure 1 The mould of bone cement specimens for biomechanical test. (A) PTFE mould and metal endplate for compressive test.
(B) PTFE mould and metal endplate for bending test. (C) Preparation of cylindrical specimens for compressive test. (D) Preparation
of rectangular specimen for bending test. (E) Final appearance of the specimens for mechanical test.
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prior to and after immersion in PBS
The specimens for test were prepared as following [29].
Chitosan or HACC was added into PMMA powder (referred to
as PMMAeC and PMMAeH, respectively) at a 20% mass ratio,
and uniformly mixed. Then the powder was mixed with the
monomer at a ratio of 1.5 mL/2 g [9]. Bone cements were
poured into the mould for the compression and bending
test, and fixed with PTFE endplates and C-shape fixture for
4 h. After the bone cements were hardened, the endplate
and C-shape fixture were removed and then the cylindrical
and rectangular test specimens were taken out for the
biomechanical test. The specimens of PMMA and
gentamicin-loaded PMMA (PMMAeG) were also prepared
using the same method.Figure 2 Compressive and bending tests for bone cement speThe ultimate compressive strength and compressive
modulus of each specimen were determined according to
ISO 5883-2002 standard using a universal testing machine
(Instron 8874, Instron), operating at a crosshead speed of
5 mm/min (Fig. 2A) [29]. The flexural strength and modulus
for each cement were carried out using a standard four-
point bending method according to ISO 5883-2002, oper-
ating with a span of 20 mm at a crosshead speed of 2 mm/
min (Fig. 2B) [29]. The load and deflection were recorded
until failure of each sample. Loadedeformation curves and
stressestrain curves were plotted and the strength and
modulus were automatically calculated and recorded by
the built-in to the equipment. Five samples were tested for
each kind of cements. To investigate further the effect of
HACC or chitosan degradation on the mechanical properties
of PMMA-based bone cements, all mechanical tests werecimens. (A) Compressive tests. (B) Four-point bending tests.
60 H. Tan et al.performed again after the specimens were soaked in
phosphate buffered saline (PBS) for 28 days at 37 C with
shaking at 100 rpm.
Preparation of cement implant for animal
experiments
HACC with 26% DS or chitosan was incorporated into PMMA
powder at a mass ratios of 20%. Then the powder was mixed
with the monomer at a ratio of 1.5 mL/2 g [9]. Bone cement
was poured into a syringe with an internal diameter of 4 mm,
and was maintained for 4 h’ fixation under external pres-
sure. After the bone cement hardened, it was pushed out
and cut into a 1.0-cm specimen for the in vivo implantation.
The PMMA bone cement and gentamicin-loaded PMMA were
also prepared using the same method. All cements were
sterilized by 25 kGy of 60Co irradiation prior to implantation.
Implantation of bone cement
Twelve female adult New Zealand white rabbits were pro-
vided by animal laboratory, Shanghai Ninth People’s Hospi-
tal, each weighing 2.51  0.40 kg, were used for animal
experiments. General anaesthesia was induced by intra-
muscular injection with 2% xylazine at a dose of 12 mg/kg
and ketamine at a dose of 80 mg/kg. After anaesthesia, the
hind legs were shaved and the skin was cleaned with 75%
alcohol. During surgery, the animal was positioned in a su-
pine position, the hind legs were sterilized by betadine, and
the body was covered with a sterile sheet. Then a 1.5-cm
long longitudinal surgical incision was made at the lateral
side of the femoral condyle. The subcutaneous tissues were
dissociated, and the cortical bone of the femur was exposed.
A lacuna with 1 cm in depth was prepared with a drill with
4 mm of diameter, and the cylindrical bone cement was
implanted into the lacuna. After surgery, each rabbit was
raised in a single cage, and intramuscularly injected with
tetracycline (SigmaeAldrich; Buchs, SG, Switzerland) at a
dose of 50 mg/kg 5 weeks after surgery, and also intramus-
cularly injected with calcein (SigmaeAldrich) at a dose of
8 mg/kg 2 days prior to sacrifice. After 6 weeks, rabbits were
sacrificed, and the femoral condyles were collected for the
following observations. Animals were randomly assigned into
four groups with three rabbits in each group. The PMMA
cement (PMMA), gentamicin-loaded PMMA (PMMAeG),
chitosan-loaded PMMA (PMMAeC), and HACC-loaded PMMA
(PMMAeH) were implanted in each group, respectively.
Ethical approval for undertaking this animal experiment was
obtained from the institutional ethics board of the Shanghai
Ninth People’s Hospital.
Scanning electron microscopy of cementebone
interface
After sacrifice, the distal femur was collected under aseptic
condition, and fixed in 4% paraformaldehyde for 48 h. The
specimen was rinsed with running water for 24 h, and
subsequently dehydrated through a series of graded
ethanol solutions (50%, 60%, 70%, 80%, 90%, 95%, and 100%).
The samples were placed into the embedded device con-
taining methylmethacrylate monomer (Technovit 9100;Technovit, Wehrheim, Germany), which was then placed in
a negative-pressure vacuum dryer for 24 h of solidification.
Then the embedded fragments containing tissue specimens
were collected and cut into 2-mm sections with a micro-
tome (Leica SP 1600; Leica, Wetzlar, Germany). The spec-
imens were then sputter-coated with gold, and the
interface between bone cement and bone tissue was
observed using a scanning electron microscope (Jeol JSM-
6310LV; Jeol Ltd., Tokyo, Japan) [9].
Fluorescence microscopy of new bone formation
around bone cement
Specimens were prepared as described above. The
embedded fragments containing tissue specimens were
collected and cut into 150-mm sections with a microtome
(Leica SP 1600). Sections were then adhered to organic glass
slides and compressed for 24 h. The thickness of the sections
was polished to 50 mm using P300, P800, and P1200 abrasive
paper, and then burnished with flannelette and abradum to
20e30 mm. Finally, the fluorescence of tetracycline and
calcein in bone tissues surrounding the bone cement was
visualized using a confocal laser scanning microscopy (CLSM,
Leica TCS SP2; Leica Microsystems, Heidelberg, Germany).
Statistical analysis
All quantitative data were expressed as the mean standard
deviation. Statistical analysis of data was carried out by
analysis of variance (ANOVA) to determine the presence of
any significant difference among the four groups, Tukey’s
multiple post-hoc comparison tests were used to determine
the statistical difference. The compressive and flexural
properties of substrates prior to and after immersion in SBF
were compared using the paired-samples t test. A p value
<0.05 was set as statistically significant difference. Statis-
tical analyses were performed using SPSS software version
15.0 (SPSS Inc., Chicago, IL, USA).
Results
Compressive properties of PMMA loaded with HACC
at different mass ratios
Thecompressive strengthandelasticmodulus ofPMMA loaded
with HACC at different mass ratios are shown in Fig. 3. The
compressive strength of HACC-loaded PMMA bone cements
gradually reduced with the increases of mass ratio. The mean
compressive strengths at mass ratios of 15%, 20%, 30%, and
40% were 79.82  4.54 MPa, 78.5  2.87 MPa,
70.01  4.29 MPa, and 57.72  9.56 MPa, respectively, in
which PMMAeH at mass ratios of 15%, 20%, and 30% were still
higher than the minimal value of 70 MPa defined in ISO 5883-
2002 [29]. The elastic modulus of PMMAeH bone cements also
showed a gradual reduction with the increases of the HACC/
PMMA mass ratio. The mean elastic modulus at mass ratios of
15%, 20%, 30% and 40% was 1927.91  51.45 MPa,
1741.68  312.67 MPa, 1410.15  438.22 MPa, and
1437.61  266.13 MPa, respectively, and there was no sig-
nificant difference among PMMA bone cements with mass
Figure 3 The compressive strength and modulus of
HACC-loaded PMMA bone cements at mass ratios of 15%,
20%, 30%, and 40%. HACC Z hydroxypropyltrimethyl ammo-
nium chloride chitosan; PMMA Z polymethylmethacrylate;
PMMAeG Z gentamicin-loaded PMMA.
Figure 4 Compressive properties of four PMMA bone cements
prior to and after 4 weeks of immersion in PBS. The results are
shown for (A) compressive strength and (B) compressive
modulus. * denotes a significant difference compared with
PMMA and PMMAeG prior to immersion in PBS (p < 0.05). **
denotes a significant difference compared with PMMA and
PMMAeG after immersion in PBS (p < 0.01). *** denotes a sig-
nificant difference compared with PMMAeH prior to immersion
(p < 0.01). PMMA Z polymethylmethacrylate;
PMMAeC Z chitosan-loaded PMMA bone cement;
PMMAeG Z gentamicin-loaded PMMA; PMMAeH Z 26% HACC-
loaded PMMA bone cement.
Quaternised chitosan-loaded PMMA bone cement 61ratios of 20%, 30%, and 40% (p > 0.05). In the present study,
the PMMA bone cement loaded with HACC at a 20% mass ratio
showed higher compressive strength (78.5  2.87 MPa) and
lower elasticmodulus (1741.68 312.67MPa). Therefore, the
20% mass ratio was selected for incorporation of HACC or
chitosan into PMMA bone cement in subsequent experiments.
Mechanical properties of bone cement prior to and
after immersion in PBS
As shown in Fig. 4, the ultimate compressive strength of
PMMA, PMMAeG, PMMAeC, and PMMAeH prior to immersion
in PBS was 94.99  3.47 MPa (Coefficient of Variation (CV),
3.6%), 93.66  1.12 MPa (CV, 1.2%), 77.67  3.68 MPa (CV,
4.7%), and 75.87  3.74 MPa (CV, 4.9%) respectively. The
compressive modulus of the specimens prior to immersion in
PBS was 2.30  0.06 GPa (CV, 2.6%), 2.21  0.00 GPa (CV,
0.0%), 1.89  0.16 GPa (CV, 8.4%), and 1.76  0.09 GPa (CV,
5.1%) for PMMA, PMMAeG, PMMAeC, and PMMAeH, respec-
tively. Both the compressive strength and modulus of
PMMAeC or PMMAeHwere significantly decreased compared
with PMMAor PMMAeG (p< 0.05). After 4weeks immersion in
PBS, the compressive strength and modulus of four PMMA-
based bone cements decreased significantly as compared
with that prior to immersion (p < 0.05). Meanwhile the
compressive strength and modulus of PMMAeC or PMMAeH
were also significant lower than that of PMMA or PMMAeG
after 4 weeks immersion in PBS (p < 0.01). Compressivestrength of PMMA, PMMAeG, PMMAeC, and PMMAeH was
79.76  1.05 MPa (CV, 1.3%), 81.14  3.03 MPa (CV, 3.7%),
66.63 3.81 MPa (CV, 5.7%), and 55.73 4.51 MPa (CV, 8.1%)
respectively. Compressive modulus of PMMA, PMMAeG,
PMMAeC, and PMMAeH was 2.09  0.09 MPa (CV, 4.3%),
1.98  0.05 MPa (CV, 2.5%), 1.71  0.08 MPa (CV, 4.6%), and
1.15  0.11 MPa (CV, 9.5%), respectively.
The bending strength of PMMA, PMMAeG, PMMAeC, and
PMMAeH prior to immersion in PBS was 64.8  5.97 MPa (CV,
9.2%), 61.5  10.8 MPa (CV, 17.5%), 43.4  8.25 MPa (CV,
19.1%), and 44.72  5.83 MPa (CV, 13.0%), respectively,
whereas 53.63  1.56 MPa (CV, 2.9%), 50.20  3.04 MPa (CV,
6.1%), 38.12 2.03 MPa (CV, 5.4%), and 30.72 2.66MPa (CV,
8.7%) after 4 weeks immersion in PBS, respectively, with the
greatest reduction found in PMMAeC and PMMAeH (p< 0.01;
Fig. 5A). There was no significant difference in the bending
modulus among PMMA (1.66  0.15 MPa, CV, 9%), PMMAeG
Figure 5 Bending properties of four PMMA bone cements
prior to and after 4 weeks of immersion in PBS. The results are
shown for (A) flexural strength and (B) flexural modulus. * de-
notes a significant difference compared with PMMA and
PMMAeG prior to immersion in PBS (p < 0.05). ** denotes a
significant difference compared with PMMA and PMMAeG after
immersion in PBS for flexural strength (p < 0.01). *** denotes a
significant difference compared with PMMA, PMMAeG, and
PMMAeC after immersion for flexural modulus. **** denotes a
significant difference compared with PMMAeH prior to im-
mersion (p < 0.01). PMMA Z polymethylmethacrylate;
PMMAeC Z chitosan-loaded PMMA bone cement;
PMMAeG Z gentamicin-loaded PMMA; PMMAeH Z 26% HACC-
loaded PMMA bone cement.
62 H. Tan et al.(1.61 0.20 MPa, CV, 12.4%), PMMAeC (1.41 0.39 MPa, CV,
27.6%), and PMMAeH (1.46  0.14 MPa, CV, 9.6%) prior to
immersion in PBS (Fig. 5B). After 4 weeks immersion in PBS,
the elastic modulus of PMMA, PMMAeG, PMMAeC, and
PMMAeHwas 1.44 0.07GPa (CV, 4.9%), 1.38 0.04GPa (CV,
2.9%), 1.35  0.20 GPa (CV, 1.2%), and 0.86  0.08 GPa (CV,
9.3%), respectively, which was significantly lower than that
prior to immersion (p < 0.01; Fig. 5B).Scanning electron microscopy of cementebone
interface
Scanning electron microscopy showed the interfacial gap
between the bone cement and the surrounding bone tissuesin the femoral condyle specimens from PMMA, PMMAeG,
and PMMAeC groups, and the gap was mostly apparent in
the specimens of PMMAeG group (Fig. 6). However, good
osteointegration at the interface between bone cement
and the surrounding bone tissues was observed in the
specimens of PMMAeH group (Fig. 6).
Fluorescence labelled new bone around cement
The bright yellow fluorescence labelling of tetracycline and
green fluorescence labelling of calcein in the newly formed
bone surrounding thecement are shown in Fig. 7.Moreobvious
fluorescence labelling was detected in the PMMA, PMMAeC,
and PMMAeH groups as compared with that in the PMMAeG
group, and the most remarkable fluorescence labelling was
observed in the specimens of the PMMAeH group.
Discussion
Major findings and breakthrough
PMMA is now widely used to augment the osteoporotic
vertebral compression fractures [1e3,6]. However, the
elastic modulus of PMMA is 2e3 GPa, whereas the osteo-
porotic vertebral cancellous bone was 0.05e0.08 GPa
[30,31]. The stiffness of the vertebral body augmented with
PMMA significantly increases in relation to the adjacent
osteoporotic vertebral segment. The mechanical mismatch
may cause stress shielding on adjacent segments, which
may aggravate the osteoporosis of the adjacent vertebral
body and result in the occurrence of fractures [5e7,32].
Therefore, a reduction of elastic modulus of PMMA may
improve its mechanical compatibility, and increase the
therapeutic efficacy of vertebroplasty. Our findings
demonstrate that PMMA bone cement incorporated with
chitosan or HACC significantly reduced the mechanical
strength of the bone cement, notably elastic modulus, in
relation to PMMA or gentamicin-loaded PMMA. Reductions
of mechanical strength were detected in PMMA, PMMAeC,
PMMAeH, and PMMAeG bone cements after 4 weeks’ im-
mersion in PBS as compared with those prior to immersion,
and the greatest reduction was observed in the PMMAeH
bone cement, which had elastic modulus closer to that of
the human cancellous bone. Therefore, it is considered that
PMMAeH bone cement has a potential to reduce the
occurrence of adjacent vertebral body fracture caused by
stress shielding in vertebroplasty. In addition, our previous
study demonstrated improvement in the polymerization
temperature and curing time of the PMMAeH bone cement,
which is more beneficial for the clinical application [33].
The reduction of the strength and stiffness of PMMAeC or
PMMAeH may be associated with the distribution condition
of the chitosan or HACC particles in the PMMA matrix. Our
previous study showed loose binding of these particles to the
matrix of the PMMA cement, where no chemical bonding but
only physical mixture existed between particles and PMMA
matrix was demonstrated under the high-temperature
polymerization condition [33]. Therefore, the HACC parti-
cles in PMMAeH bone cement following immersion in PBS
could release from the cement surface due to the high sol-
ubility ofHACC,whichmight be the cause leading to a further
Figure 6 Scanning electron micrograph of the interface between cement and bone tissue in different groups. Photograph B
represents the magnification of the boxed region in photograph A. A: 50 magnification, B: 250 magnification.
Quaternised chitosan-loaded PMMA bone cement 63reduction of its stiffness. The PMMAeH with low stiffness
could be less stress shielding to neighbouring bone tissue
when used in vertebral augmentation as well as in total joint
replacement. In addition, the pore structures formed on the
bone cement after the HACC dissolution may be beneficial
for osteogenesis and new bone in-growth [33].
High osseointegration is required to maintain durable and
reliable biological fixation of implant after orthopaedicsurgery, and a similar requirement is demanded in the PMMA
bonecement. PMMAbonecement is biologically inert, and the
widely used gentamicin-loaded PMMA may remarkably affect
the functions of osteogenic cells due to the local release of
high initial concentrations of antibiotics, thereby affecting
the local osseointegration [17e21,24e26]. In order to vali-
date the in vivo biological activity of PMMAeH bone cement,
the osseointegration at the implantebone interface was
Figure 7 Confocal laser scanning micrograph showed the bright yellow fluorescence labelling of tetracycline and green fluo-
rescence labelling of calcein in the newly formed bone around cement in different groups. (A) Tetracycline labelling, (B) calcein
labelling, (C) combined calcein and tetracycline labelling.
64 H. Tan et al.evaluated and compared among four types of bone cement in
the rabbit femoral condyle. The fluorescent markers tetra-
cycline andcalceinwereused to label thenewbone formation
around the implants. Following injection into the body, these
active fluorescent markers could bind with inorganic salt and
then deposit into the calcified bone matrix [34]. The present
in vivo study showed tight binding of the boneecement
interface after the PMMAeH implantation. The intensity andarea of fluorescent double labelling around the PMMAeH
cement were greater than those around PMMA, PMMAeC, or
PMMAeG cement, suggesting that the PMMAeH is more
beneficial for the formation and deposition of the new bone
tissues. This in vivo findings further validated the results ob-
tained from our previous in vitro studies that the PMMAeH
bone cement had a high bone biological activity because of
higher hydrophilicity, better stem cell proliferation, and
Quaternised chitosan-loaded PMMA bone cement 65osteogenic differentiation on its surface [27,28,33]. In addi-
tion, our findings showed poor osseointegration of the
cementebone interface in the PMMAeG group, which may be
associated with the inhibition of the local gentamicin release
on the functions of osteogenic cells [19e22].
Limitations and potential solutions
Loosening and infection are major complications after
joint replacement. We have demonstrated that PMMAeH
had improved biomechanical and biological properties
compared to the commercial PMMA cement both in vitro and
in vivo. These characteristics of cements will be beneficial
to improve the stability and osteointegration of implants. As
we plan to register PMMAeH as an anti-infection bone
cement as a medical device, the result of an animal infec-
tion prophylaxis model will be essential to its successful
clinical translation. In previous studies, we demonstrated
that this bone cement could inhibit bacterial biofilm for-
mation on its surface [28]. Now a rabbit infection prophy-
laxis model is being used to test the anti-infection ability of
PMMAeH and preliminary data have shown promising results.
In addition, in vivo mechanical testing should also be per-
formed to verify the in vitro mechanical properties.
Further essential steps and obstacles in translation
According to the regulations of the China Food and Drug
Administration, the bone cement is regulated as a class III
medical device. Firstly, the safety, toxicity, and biocom-
patibility should be evaluated according to the standards of
Biological Evaluation of Medical Devices (GB/T 16886) in
qualified testing institutions. Also, the technical standards
of this new cement should be formulated based on the
current standard of the orthopaedic implantdacrylic bone
cement (ISSO, 5883-2002). Then, the clinical trials should
be done in two separate qualified hospitals. Finally, all
documents, including the product standard, testing re-
ports, and clinical trial reports, shall be submitted ac-
cording to provisions of the drug regulatory authority under
the State Council.
Conclusions
The ideal mass ratio for HACC loaded into PMMA bone
cement was 20%, and the mechanical property of HACC-
loaded PMMA bone cement was closer to that of human
cancellous bone. The in vivo study demonstrated good
osseointegration of HACC-loaded PMMA cement with bone
tissue in relative to PMMA, PMMAeG, and PMMAeC cements,
and more new bone formation was observed around the
HACC-loaded PMMA cement. It suggested that PMMAeH
cement has a potential to be used for vertebral augmen-
tation of osteoporotic vertebral compression fractures and
fixation of prosthesis in cemented joint replacement.
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